Andrew Enrietti
Chief Administrative and Transformation OfficerViatris
PharmaceuticalsView Profile →Executive Vice President, VelociGene and Drug Safety and Pharmacometrics · Regeneron Pharmaceuticals
Brian Zambrowicz is executive vice president of VelociGene and drug safety and pharmacometrics at Regeneron Pharmaceuticals. He joined in 2015 after nearly two decades at Lexicon Pharmaceuticals, where he became executive vice president and chief scientific officer.
Last reviewed: Oct 21, 2026
Executive Vice President, VelociGene and Drug Safety and Pharmacometrics Regeneron Pharmaceuticals
Last Reviewed: October 21, 2026
Brian Zambrowicz is executive vice president of VelociGene and drug safety and pharmacometrics at Regeneron Pharmaceuticals. He joined in 2015 after nearly two decades at Lexicon Pharmaceuticals, where he became executive vice president and chief scientific officer.
Zambrowicz worked at Lexicon Pharmaceuticals from 1996 to 2015. He held positions of increasing responsibility and ultimately served as executive vice president and chief scientific officer.
He joined Regeneron in 2015. His current responsibilities cover functional genomics and VelociGene operations, together with drug safety and pharmacometrics. The portfolio combines research technologies with the scientific evaluation of drug safety and drug effects.
His career brings doctoral scientific training and prior chief scientific officer experience into executive leadership of these functions at Regeneron. The current visible company title includes drug safety and pharmacometrics, extending beyond older descriptions focused on functional genomics.
Zambrowicz earned a BS from the University of Wisconsin–Madison and a PhD from the University of Washington.